63 related articles for article (PubMed ID: 8767528)
1. Plasma cell P170 expression and response to treatment in multiple myeloma.
Patriarca F; Melli C; Damiani D; Michieli M; Michelutti A; Cavo M; Baccarani M
Haematologica; 1996; 81(3):232-7. PubMed ID: 8767528
[TBL] [Abstract][Full Text] [Related]
2. Immunocytochemical observation of multidrug resistance (MDR) p170 glycoprotein expression in human osteosarcoma cells. The clinical significance of MDR protein overexpression.
Bodey B; Taylor CR; Siegel SE; Kaiser HE
Anticancer Res; 1995; 15(6B):2461-8. PubMed ID: 8669809
[TBL] [Abstract][Full Text] [Related]
3. Elimination of chemoresistant multiple myeloma clonogenic colony-forming cells by combined treatment with a plasma cell-reactive monoclonal antibody and a P-glycoprotein-reactive monoclonal antibody.
Tong AW; Lee J; Wang RM; Dalton WS; Tsuruo T; Fay JW; Stone MJ
Cancer Res; 1989 Sep; 49(17):4829-34. PubMed ID: 2569359
[TBL] [Abstract][Full Text] [Related]
4. BCL-X expression in multiple myeloma: possible indicator of chemoresistance.
Tu Y; Renner S; Xu F; Fleishman A; Taylor J; Weisz J; Vescio R; Rettig M; Berenson J; Krajewski S; Reed JC; Lichtenstein A
Cancer Res; 1998 Jan; 58(2):256-62. PubMed ID: 9443402
[TBL] [Abstract][Full Text] [Related]
5. [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].
Luo SK; Li J; Hong WD; Zhao Y; Tong XZ
Ai Zheng; 2005 Dec; 24(12):1518-21. PubMed ID: 16351805
[TBL] [Abstract][Full Text] [Related]
6. Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
Shi H; Lu D; Shu Y; Shi W; Lu S; Wang K
Cancer Invest; 2008 May; 26(4):344-51. PubMed ID: 18443954
[TBL] [Abstract][Full Text] [Related]
7. The expression of the multidrug transporter P-170 glycoprotein in remission phase is associated with early and resistant relapse in multiple myeloma.
Musto P; Lombardi G; Matera R; Carotenuto M
Haematologica; 1991; 76(6):513-6. PubMed ID: 1687943
[TBL] [Abstract][Full Text] [Related]
8. The expression of the multidrug resistance related glycoprotein in adult acute lymphoblastic leukemia.
Savignano C; Geromin A; Michieli M; Damiani D; Michelutti A; Melli C; Fanin R; Baccarani M
Haematologica; 1993; 78(5):261-3. PubMed ID: 7906239
[TBL] [Abstract][Full Text] [Related]
9. p170-dependent multidrug resistance. Restoring full sensitivity to idarubicin with verapamil and cyclosporin A derivatives.
Michieli M; Damiani D; Michelutti A; Melli C; Russo D; Fanin R; Baccarani M
Haematologica; 1994; 79(2):119-26. PubMed ID: 7914881
[TBL] [Abstract][Full Text] [Related]
10. Cancer chemotherapy does not enhance MDR-associated 170 kd glycoprotein expression in normal blood mononuclear cells.
Geromin A; Michieli M; Damiani D; Michelutti A; Vigevani E; Signor M; Fanin R; Baccarani M
Haematologica; 1992; 77(6):470-2. PubMed ID: 1363234
[TBL] [Abstract][Full Text] [Related]
11. P-glycoprotein expression and prognostic value in acute myeloid leukemia.
Senent L; Jarque I; Martín G; Sempere A; González-García Y; Gomis F; Pérez-Sirvent M; De La Rubia J; Sanz MA
Haematologica; 1998 Sep; 83(9):783-7. PubMed ID: 9825574
[TBL] [Abstract][Full Text] [Related]
12. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of multidrug resistance-associated p170-glycoprotein in acute non-lymphocytic leukemia.
Michieli M; Damiani D; Geromin A; Michelutti A; Fanin R; Raspadori D; Russo D; Visani G; Dinota A; Pileri S
Eur J Haematol; 1992 Feb; 48(2):87-92. PubMed ID: 1347749
[TBL] [Abstract][Full Text] [Related]
14. Chemoresistance and multiple myeloma: from biological to clinical aspects.
Rossi JF
Stem Cells; 1995 Aug; 13 Suppl 2():64-71. PubMed ID: 8520514
[TBL] [Abstract][Full Text] [Related]
15. Expression of multidrug resistance gene (MDR-1) in human normal leukocytes.
Damiani D; Michieli M; Michelutti A; Geromin A; Raspadori D; Fanin R; Savignano C; Giacca M; Pileri S; Mallardi F
Haematologica; 1993; 78(1):12-7. PubMed ID: 8098310
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance.
Jaksic W; Trudel S; Chang H; Trieu Y; Qi X; Mikhael J; Reece D; Chen C; Stewart AK
J Clin Oncol; 2005 Oct; 23(28):7069-73. PubMed ID: 16129840
[TBL] [Abstract][Full Text] [Related]
17. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
18. Drug resistance in multiple myeloma.
Sonneveld P
Pathol Biol (Paris); 1999 Feb; 47(2):182-7. PubMed ID: 10192886
[TBL] [Abstract][Full Text] [Related]
19. A unique human ovarian carcinoma cell line expressing CD34 in association with selection for multidrug resistance.
Minderman H; Vanhoefer U; Toth K; Minderman MD; Rustum YM
Cancer; 1996 Dec; 78(11):2427-36. PubMed ID: 8941015
[TBL] [Abstract][Full Text] [Related]
20. Drug resistance in multiple myeloma.
Sonneveld P; Lokhorst HM; Vossebeld P
Semin Hematol; 1997 Oct; 34(4 Suppl 5):34-9. PubMed ID: 9408959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
